any agm feedback?, page-4

It is encouraging to know that there is a readership on this board of at least 3 or 4 and not just accidental dead end traffic. Hence these additional notes.

The consumers of NSP products are all specialised entities so that general publicity has limited value. However to trigger the investment community interest something imaginative such as the SpermSep instrument is required since it connects high tech and the birth of babies. However the 'minor' modifications are still not ready for the final clinical trial to commence. [The NSP presentation of 30 June 08 (slides 14 and 16) lists first sale of SpermSep to be in March 09 and the objective to have sold 200 units by 2010!]

BioInquire. There are 150 clients presently testing/ trying out the software offered. A revenue figure of $150 000 was mentioned but is somewhat vague as there are different levels of subscription. My inference is that if these clients find it as rapid and as effective as the product claims they would go for the high level. Labour saving devices generally sell well particularly if a research paper is a by product. The client base is research groups so that there may initially be a time lag before building up a commitment. The estimated segment revenue for this FY remains at $1.2M.

Expedeon patent infringement proceedings. In response to NSP taking court action, negotiations have taken place and Expedeon have actually asked what kind of gel cassette NSP would find acceptable. This implies that Expedeon accepts the infringement objection and is trying to settle the issue out of court. The distributor for both companies, Pierce, is highly embarrassed by all of this. They remain the NSP distributor.

Additional SingaPharm points. Since the new Plasma manufacturing business case looks very good just what is the supply of source plasma? Note that the ASX ann of Thurs 24 Nov gives its status as, "Has secured the supply of plasma for the next three years." We were assured that the supply is secure but the source of supply could not be divulged at the present time.

A new logo has been designed and is already in use on Gel packs. We were not given a justification for the change. The 'old' one gave an appropriate impression of 3-D twisted strands of DNA. In the new design of concentric semicircles there is a strong inference of gold standard by use of gold print. Brands are often recognised by logos and distinctive colours so that once adopted they should not be allowed to change dramatically.

The chairman also emphasised that by the next AGM the board would be 'refreshed' to reflect the upgraded position of the company. Presumably this means additional members of specialised calibre. What other interpretation? They washed their faces?

The forecast operating profit of $1.8 M for 2011FY remains as is.

These notes are intended to supplement the AGM presentation that was put up today (Mon).

Juke